Literature DB >> 20109735

Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis.

Patrick M Schlievert1, Kristi L Strandberg, Ying-Chi Lin, Marnie L Peterson, Donald Y M Leung.   

Abstract

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains have emerged as serious health threats in the last 15 years. They are associated with large numbers of atopic dermatitis skin and soft tissue infections, but when they originate from skin and mucous membranes, have the capacity to produce sepsis and highly fatal pulmonary infections characterized as necrotizing pneumonia, purpura fulminans, and postviral toxic shock syndrome. This review is a discussion of the emergence of 3 major CA-MRSA organisms, designated CA-MRSA USA400, followed by USA300, and most recently USA200. CA-MRSA USA300 and USA400 isolates and their methicillin-sensitive counterparts (community-associated methicillin-sensitive S aureus) typically produce highly inflammatory cytolysins alpha-toxin, gamma-toxin, delta-toxin (as representative of the phenol soluble modulin family of cytolysins), and Panton Valentine leukocidin. USA300 isolates produce the superantigens enterotoxin-like Q and a highly pyrogenic deletion variant of toxic shock syndrome toxin 1 (TSST-1), whereas USA400 isolates produce the superantigens staphylococcal enterotoxin B or staphylococcal enterotoxin C. USA200 CA-MRSA isolates produce small amounts of cytolysins but produce high levels of TSST-1. In contrast, their methicillin-sensitive S aureus counterparts produce various cytolysins, apparently in part dependent on the niche occupied in the host and levels of TSST-1 expressed. Significant differences seen in production of secreted virulence factors by CA-MRSA versus hospital-associated methicillin-resistant S aureus and community-associated methicillin-sensitive S aureus strains appear to be a result of the need to specialize as the result of energy drains from both virulence factor production and methicillin resistance. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109735      PMCID: PMC2814367          DOI: 10.1016/j.jaci.2009.10.039

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  95 in total

1.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.

Authors:  Soju Chang; Dawn M Sievert; Jeffrey C Hageman; Matthew L Boulton; Fred C Tenover; Frances Pouch Downes; Sandip Shah; James T Rudrik; Guy R Pupp; William J Brown; Denise Cardo; Scott K Fridkin
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

Review 2.  Virulence regulation in Staphylococcus aureus: the need for in vivo analysis of virulence factor regulation.

Authors:  Alexa A Pragman; Patrick M Schlievert
Journal:  FEMS Immunol Med Microbiol       Date:  2004-10-01

3.  Sequence analysis of the Staphylococcus aureus srrAB loci reveals that truncation of srrA affects growth and virulence factor expression.

Authors:  Alexa A Pragman; Lisa Herron-Olson; Laura C Case; Sara M Vetter; Evan E Henke; Vivek Kapur; Patrick M Schlievert
Journal:  J Bacteriol       Date:  2007-08-10       Impact factor: 3.490

4.  Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1.

Authors:  C J Hovde; J C Marr; M L Hoffmann; S P Hackett; Y I Chi; K K Crum; D L Stevens; C V Stauffacher; G A Bohach
Journal:  Mol Microbiol       Date:  1994-09       Impact factor: 3.501

5.  Subunit stoichiometry of staphylococcal alpha-hemolysin in crystals and on membranes: a heptameric transmembrane pore.

Authors:  J E Gouaux; O Braha; M R Hobaugh; L Song; S Cheley; C Shustak; H Bayley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

6.  Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic shock syndrome.

Authors:  P M Schlievert; M T Osterholm; J A Kelly; R D Nishimura
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

7.  Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C.

Authors:  P M Schlievert
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

8.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Authors:  R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

9.  Toxic-shock syndrome associated with phage-group-I Staphylococci.

Authors:  J Todd; M Fishaut; F Kapral; T Welch
Journal:  Lancet       Date:  1978-11-25       Impact factor: 79.321

10.  Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome.

Authors:  B A Crass; M S Bergdoll
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

View more
  65 in total

1.  A single, engineered protein therapeutic agent neutralizes exotoxins from both Staphylococcus aureus and Streptococcus pyogenes.

Authors:  Ningyan Wang; Daiva M Mattis; Eric J Sundberg; Patrick M Schlievert; David M Kranz
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

2.  Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum.

Authors:  Lianghua Bin; Michael G Edwards; Ryan Heiser; Joanne E Streib; Brittany Richers; Clifton F Hall; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2014-08-23       Impact factor: 10.793

3.  Staphylococcal superantigens cause lethal pulmonary disease in rabbits.

Authors:  Kristi L Strandberg; Jessica H Rotschafer; Sara M Vetter; Rebecca A Buonpane; David M Kranz; Patrick M Schlievert
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

4.  Adaptive Immunity Against Staphylococcus aureus.

Authors:  Hatice Karauzum; Sandip K Datta
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

5.  Effect of non-absorbent intravaginal menstrual/contraceptive products on Staphylococcus aureus and production of the superantigen TSST-1.

Authors:  Patrick M Schlievert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

6.  Passive therapy with humanized anti-staphylococcal enterotoxin B antibodies attenuates systemic inflammatory response and protects from lethal pneumonia caused by staphylococcal enterotoxin B-producing Staphylococcus aureus.

Authors:  Melissa J Karau; Mulualem E Tilahun; Ashton Krogman; Barbara A Osborne; Richard A Goldsby; Chella S David; Jayawant N Mandrekar; Robin Patel; Govindarajan Rajagopalan
Journal:  Virulence       Date:  2016-12-07       Impact factor: 5.882

7.  Receptor-dependent and -independent immunomodulatory effects of phenol-soluble modulin peptides from Staphylococcus aureus on human neutrophils are abrogated through peptide inactivation by reactive oxygen species.

Authors:  Huamei Forsman; Karin Christenson; Johan Bylund; Claes Dahlgren
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

8.  Transplantation of human skin microbiota in models of atopic dermatitis.

Authors:  Ian A Myles; Kelli W Williams; Jensen D Reckhow; Momodou L Jammeh; Nathan B Pincus; Inka Sastalla; Danial Saleem; Kelly D Stone; Sandip K Datta
Journal:  JCI Insight       Date:  2016-07-07

Review 9.  Device-Associated Menstrual Toxic Shock Syndrome.

Authors:  Patrick M Schlievert; Catherine C Davis
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

10.  Systemic inflammatory response elicited by superantigen destabilizes T regulatory cells, rendering them ineffective during toxic shock syndrome.

Authors:  Ashenafi Y Tilahun; Vaidehi R Chowdhary; Chella S David; Govindarajan Rajagopalan
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.